Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004009117 - TOCOLYTIC AGENT COMPRISING EP2 AGONIST AS THE ACTIVE INGREDIENT

Publication Number WO/2004/009117
Publication Date 29.01.2004
International Application No. PCT/JP2003/009091
International Filing Date 17.07.2003
Chapter 2 Demand Filed 22.01.2004
IPC
A61K 31/5575 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes
5575having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
CPC
A61K 31/5575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
5575having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61P 1/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
08for nausea, cinetosis or vertigo; Antiemetics
A61P 1/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
12Antidiarrhoeals
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
A61P 15/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
08for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 25/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
06Antimigraine agents
Applicants
  • ONO PHARMACEUTICAL CO., LTD. [JP]/[JP] (AllExceptUS)
  • HARADA, Hiroyuki [JP]/[JP] (UsOnly)
  • SHIROYA, Tsutomu [JP]/[JP] (UsOnly)
  • OBATA, Takaaki [JP]/[JP] (UsOnly)
Inventors
  • HARADA, Hiroyuki
  • SHIROYA, Tsutomu
  • OBATA, Takaaki
Agents
  • OHIE, Kunihisa
Priority Data
2002-21029018.07.2002JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) TOCOLYTIC AGENT COMPRISING EP2 AGONIST AS THE ACTIVE INGREDIENT
(FR) AGENT TOCOLYTIQUE COMPRENANT COMME PRINCIPE ACTIF UN AGONISTE DE EP2
(JA) EP2アゴニストを有効成分とする子宮収縮抑制剤
Abstract
(EN)
A tocolytic agent containing an EP2 agonist as the active ingredient. A selective EP2 agonist such as a prostaglandin derivative represented by the following general formula (I): (I) wherein R1 represents carboxy, etc.; RI-1 represents halogen, etc.; RI-2 represents hydrogen, hydroxy, etc.; RI-3 represents hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, etc.; and nI is 0 or an integer of 1 to 4; its ester, its nontoxic salt or cyclodextrin clathrates thereof have an tocolytic effect and, therefore, are useful in treating diseases originating in uterine contraction such as menstrual difficulty.
(FR)
L'invention concerne un agent tocolytique contenant comme principe actif un agoniste de EP2. Elle concerne aussi un agoniste de EP2 sélectif tel qu'un dérivé de prostaglandine correspondant à la formule générale (I), dans laquelle: R1 représente carboxy, etc.; RI-1 représente halogène, etc.; RI-2 représente hydrogène, hydroxy, etc.; RI-3 représente hydrogène, alkyle C1-8, alcényle C2-8, alkynyle C2-8, etc.; et nI vaut 0 ou représente un nombre entier de 1 à 4. Ledit agoniste, ses esters, ses sels non toxiques et ses clathrates de cyclodextrin ont un effet tocolytique et, pour cette raison, ils peuvent être utilisés pour traiter des troubles résultant de contractions utérines, tels que des problèmes menstruels.
(JA)
not available
Also published as
Latest bibliographic data on file with the International Bureau